NCT03475862 - Nasal Human Abuse Potential of PTI-821 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

July 31, 2017

Study Completion Date

December 15, 2017

Conditions

Opioid Abuse Nondependent

Interventions

DRUG

PTI-821 capsule Manipulated

PTI-821 (oxycodone) 40 mg extended release capsule

DRUG

PTI-821 Non-manipulated

PTI-821 (oxycodone) 40 mg capsule extended release capsule

DRUG

OxyContin

Crushed OxyContin (oxycodone) extended-release 40 mg tablet

OTHER

Placebo

Matching placebos for PTI-821 and oxycodone IR

DRUG

Oxycodone

Crushed oxycodone 40 mg immediate release tablet

Trial Locations (1)

PRA-EDS, Salt Lake City